In response to ongoing market uncertainty, PacBio is executing a plan to reduce both headcount across all functions and non-headcount related expenses to lower its annualized non-GAAP operating ...

April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025. Preliminary First Quarter Results Our preliminary ...

Pacific Biosciences of California (NASDAQ:PACB) stock price jumped 22% on Wednesday after the company laid down its preliminary Q1 numbers. The company expects its Q1 revenue to be $36.9M ...

Shares of Pacific Biosciences of California climbed after the company backed its prior outlook and announced cuts to its spending and workforce. The stock rose 9.6% to $1.32 in mid-morning trading.

PacBio reported $36.9 million in Q1 revenue, beating consensus, with record consumable sales and steady Revio system pull-through. Company to cut $45–$50 million in annualized costs by year-end ...

Pacific Biosciences of California backed its prior outlook and announced cuts to its spending and workforce, boosting shares even before the tariffs announcement. PacBio also said it is executing ...

PacBio to Cut Jobs, Lower Spending Over NIH Funding Cuts and Tariffs By Sneha S K (Reuters) -Gene sequencing equipment maker PacBio plans to cut around 120 jobs and lower expenses due to fresh ...

Pacific Biosciences is reducing both headcount and spending across its DNA sequencing business, in the face of escalating global tariffs and threats to federal biomedical research grants.

In response to ongoing market uncertainty, PacBio is executing a plan to reduce both headcount across all functions and non-headcount related expenses to lower its annualized non-GAAP operating ...

MENLO PARK, Calif. - Pacific Biosciences of California, Inc. (NASDAQ: PACB), known as PacBio, reported preliminary first-quarter revenues of $36.9 million, a slight decrease from the $38.8 million ...

Our preliminary revenue for the first quarter met our expectations despite impacts from ongoing uncertainty in NIH funding in the United States and broader economic headwinds affecting the industry.